Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Timothy Eric Newhook

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6663-459X; OpenAlex author ID A5069580577. Sources: OpenAlex.

Their work

Papers
14 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 3 papers · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 14

  1. Presentation, Management, and Outcomes of Cyst-Associated Pancreatic Cancer Versus Classic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002608↗
  2. The benefit of adjuvant chemotherapy following pancreaticoduodenectomy for pancreatic adenocarcinoma depends on response to neoadjuvant therapy. Co-author DOI 10.1002/jso.27689↗
  3. Quality of superior mesenteric and hepatic artery dissection in robotic pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1002/jhbp.1218↗
  4. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000005184↗
  5. Prognostic significance of preoperative and postoperative CA 19-9 normalization in pancreatic adenocarcinoma treated with neoadjuvant therapy or surgery first. First author DOI 10.1002/jso.26989↗
  6. AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatment sequencing. Co-author DOI 10.1016/j.suronc.2021.101673↗
  7. Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy. Co-author DOI 10.1002/jso.26650↗
  8. Impact of Intraoperative Dexamethasone on Surgical and Oncologic Outcomes for Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-09013-4↗
  9. ASO Author Reflections: Tumor Biology and Safe Surgery Remain Major Determinants of Survival After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-020-09087-0↗
  10. CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. First author DOI 10.1158/1078-0432.ccr-17-2283↗
  11. Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis. Co-author DOI 10.1245/s10434-016-5116-4↗
  12. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer. First author DOI 10.1016/j.neo.2014.06.004↗
  13. A thirteen-gene expression signature predicts survival of patients with pancreatic cancer and identifies new genes of interest. Co-author DOI 10.1371/journal.pone.0105631↗
  14. Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epiderma… Co-author DOI 10.1593/neo.121712↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ching-Wei David Tzeng · 8 shared papers, 2021–2026 · strength 1.41
  2. Matthew H. G. Katz · 7 shared papers, 2021–2026 · strength 1.14
  3. Naruhiko Ikoma · 7 shared papers, 2021–2026 · strength 1.14
  4. Michael P. Kim · 7 shared papers, 2021–2026 · strength 1.14
  5. Jeffrey E. Lee · 7 shared papers, 2021–2026 · strength 1.14
  6. Laura R. Prakash · 5 shared papers, 2021–2023 · strength 0.68
  7. Hop S. Tran Cao · 2 shared papers, 2023–2026 · strength 0.45
  8. Timothy J. Vreeland · 2 shared papers, 2023–2024 · strength 0.34
  9. Jean‐Nicolas Vauthey · 2 shared papers, 2022–2023 · strength 0.32
  10. Rebecca Anne Snyder · 1 shared paper, 2026 · strength 0.28
  11. Todd W. Bauer · 5 shared papers, 2013–2018 · strength 0.25
  12. José Soliz · 2 shared papers, 2021 · strength 0.23
  13. Franklin A. Valdera · 1 shared paper, 2024 · strength 0.19
  14. Alexandra M. Adams · 1 shared paper, 2024 · strength 0.19
  15. Patrick M. McCarthy · 1 shared paper, 2024 · strength 0.19
  16. Anne E. O’Shea · 1 shared paper, 2024 · strength 0.19
  17. Daniel William Nelson · 1 shared paper, 2024 · strength 0.19
  18. Elizabeth L. Carpenter · 1 shared paper, 2024 · strength 0.19
  19. James M. Lindberg · 4 shared papers, 2013–2016 · strength 0.18
  20. Yongwoo David Seo · 1 shared paper, 2023 · strength 0.17
  21. Yun Shin Chun · 1 shared paper, 2023 · strength 0.17
  22. Timothy P. DiPeri · 1 shared paper, 2022 · strength 0.16
  23. Michael James Overman · 1 shared paper, 2023 · strength 0.15
  24. Robert A. Wolff · 1 shared paper, 2023 · strength 0.15
  25. Rebecca S. Slack Tidwell · 1 shared paper, 2023 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.